Q-omics provides the consensus-scored MIR1251 profile across patient tissues and cancer cell-line models. MIR1251 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MIR1251 is differentially expressed in 3, with the highest sampling consensus in KICH. Additionally, MIR1251 RNA expression shows 12,310 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight CESC, KICH, and COAD as cancer lineages where MIR1251 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1251 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1251 survival associations across molecular data types. MIR1251 RNA expression shows survival associations in the most cancer types (9), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1251 RNA expression–survival associations across cancer types. High MIR1251 expression shows unfavorable associations in CESC, LUAD, ACC, BLCA, ESCA and CHOL. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for MIR1251 RNA expression.
This table summarizes MIR1251 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1251. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1251 shows lower tumor expression in UCEC and LUSC and higher tumor expression in KICH. The KICH box plot shows higher MIR1251 RNA expression in tumor versus normal tissue (log2 FC = +0.274, t-test p = .002).
This table shows molecular features associated with MIR1251 in patient tissues and cancer cell lines. In patient samples, MIR1251 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
